Multi-cell pathogenic gene set hybrid cell line and gene bank thereof
By constructing vectors carrying SV40LT and hTERT genes and performing cell fusion, a multi-cell pathogenic gene collection hybrid cell line was established, which solved the problem of lack of quality control substances in gene sequencing and genetic disease screening, and achieved efficient preparation of multi-gene mutations It controls objects, improves detection accuracy and work efficiency.
Patent Information
- Application Number
- CN202411049974.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-06
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-22
AI Technical Summary
In the prior art, the lack of suitable quality control substances in genetic sequencing and screening of genetic disease carriers leads to problems with detection accuracy and efficiency, especially the difficulty in preparing quality control substances of multiple pathogenic genes, which affects prenatal diagnosis and inheritance. Accuracy and promotion of disease screening.
By constructing vectors carrying SV40LT and hTERT genes, transfecting cells and performing cell fusion, a multi-cell pathogenic gene collection hybrid cell line is established, and multiple cell lines are fusion and combined drug screening are achieved to create long-lived and efficient immortalization performance. hybrid cell lines used to prepare quality control substances for multigene mutations or multivariate sites.
The construction of multi-cell pathogenic gene collection hybrid cell lines has been realized, which can effectively replace multiple cell lines, improve the production efficiency and management convenience of quality control substances, solve the problem of preparation of various pathogenic genes, and improve the Test accuracy and work efficiency.
Smart Images

Figure CN118995813A_ABST
Abstract
Description
Technical Field
[0001] The invention discloses a multi-cell pathogenic gene set hybrid cell line and a gene library thereof, which are used for preparing gene detection quality control materials in the medical biology field. Background Art
[0002] Since the implementation of prenatal diagnosis, prenatal diagnosis or screening projects such as fetal chromosome karyotype analysis, fluorescence in situ hybridization, gene chips, gene sequencing, maternal plasma fetal free DNA detection, and DNA electrophoresis have been carried out.
[0003] Laboratory quality control is the guarantee of accurate results. However, because prenatal diagnosis targets rare diseases, samples that can be used as quality control materials for the tested cases are difficult to obtain. The lack of quality control materials directly affects the access and quality supervision of new prenatal diagnosis projects.
[0004] In order to solve the problem of lack of quality control materials for prenatal screening and prenatal diagnosis, domestic research on the renewable utilization technology of rare disease samples has been conducted. In 2005, it was reported that the EB virus transfection method was used to establish a chromosomal abnormal lymphocyte line with difficult, rare, and easily misdiagnosed karyotypes (CN1916183A / 200510091259.2), which was used as a quality control cell for fetal chromosome karyotype analysis. It has since been expanded to be used in the preparation of quality control materials for prenatal testing of other rare diseases. Because the higher the homology between the quality control material and the test object, the better, and amniotic fluid cells are mainly used in prenatal diagnosis, it was reported in 2009 that the SV40LT gene transfection method was used to construct an amniotic fluid fibroblast cell line (CN101942413A / CN200910152257.8), which transformed the limited amniotic fluid cells left after prenatal diagnosis into an unlimited and renewable quality control cell line, which is mainly used to prepare quality control materials for prenatal testing of aneuploidy.
[0005] However, with the development of gene sequencing technology, the expert consensus on the clinical application of screening for common recessive single-gene genetic disease carriers before and during early pregnancy (Chinese Journal of Perinatal Medicine, 2024, 27: 3-12) released in China pointed out that "screening for carriers of multiple genetic diseases will be carried out, with target diseases ranging from dozens to hundreds". According to the quality control access of new projects, quality control materials corresponding to the tested cases must be used as positive controls. If 50 or 100 cases of genetic diseases caused by different gene mutations are to be tested in the same batch, 50 or 100 quality control materials or quality control cell lines corresponding to the tested cases must be used. If such a large amount of quality control materials is not resolved, it will affect the development of new projects and the accuracy of test results. Kyu et al. reported that the main reason for gene sequencing errors is the lack of positive control quality control materials that can be used for calibration (The Application of Control Materials for Ongoing Quality Management of Next-Generation Sequencing in a Clinical Genetic Laboratory. Medicina. 2021). In 2011, foreign reports used genetic disease carrier screening technology and exome sequencing technology to detect 690 samples, and found that the detection rates were 0.6%-0.9% and 5.9%, respectively; in 221 pathogenic variant detections, the detection rates of the two were 1.8%-2.7% and 18.6%, respectively; and in 41 single gene disease detections, the detection rates of the two were 9.8%-14.6% and 100.0%, respectively (Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med, 2011). Therefore, there are currently no quality control materials for genetic disease carrier screening, not only because the detection targets are rare diseases, but also because there are many types of diseases and a large number of pathogenic genes. It is difficult to prepare quality control materials that contain many disease-causing genes, which affects the accuracy of the test and its promotion and application. Therefore, the preparation of quality control materials for carrier screening is a problem that has long been desired to be solved at home and abroad but has not yet been solved.
[0006] Literature reports that both the monkey virus large T antigen gene SV40LT and the telomerase catalytic subunit gene hTERT can immortalize mammalian cells (Extension of life-span by introduction of telomerase into normal human cells. Science / Immortalization by large T-antigen of the adult epididymal duct epithelium. Mol Cell Endocrinol). Based on this, the present invention constructs vectors containing different screening markers and immortalization genes, transfects cells carrying different pathogenic genes, and establishes cell lines with different screening markers and pathogenic genes. The hybrid cell line obtained by fusion of different cell lines optimizes immortalization performance due to inheriting the SV40LT and hTERT genes of each parental cell line, resists joint screening due to inheriting different screening markers of each parental cell line, and integrates pathogenic genes of multiple diseases due to inheriting different genes of each parental cell line, so that the prepared hybrid cell line is suitable for the efficient preparation of multi-gene mutation or multi-variable site quality control materials. Summary of the invention
[0007] The purpose of the present invention is to establish a cell line hybridoma technology for constructing a multi-cell pathogenic gene set hybrid cell line and a new gene library using the multi-cell pathogenic gene set hybrid cell line as the target gene collection unit.
[0008] The object of the present invention is achieved as follows: first, a cell line hybridoma technical scheme is designed, including constructing a vector SV40LTag-pcDNA3.1(-) carrying a derived neomycin G418 resistance gene and an SV40LT immortalization gene, and simultaneously constructing a vector pLPCX-hTERT carrying a puromycin PM resistance gene and an hTERT immortalization gene, and transfecting the constructed vectors into human-derived cells or animal-derived cells respectively, so that the cells transfected with the vectors are immortalized and obtain a resistance gene to either G418 or PM, and then the immortalized cell lines carrying different resistance gene selection markers are subjected to cell fusion, and the fusion is carried out. The hybrid product is screened with G418 and PM together, so that the unfused parental cell lines and their respective fused cells are killed by G418 or PM. Only the hybrid cell lines that inherit the resistance genes of the two parental cell lines and resist both G418 and PM drug screening can survive. The cell line hybridoma technology is established to be used to fuse multiple cell lines carrying different pathogenic genes into cell line hybridomas, that is, to construct a multi-cell pathogenic gene set hybrid cell line based on the fusion of multiple cell lines, so that the target pathogenic genes of multiple cell lines are collected in the hybrid cell line, and a new gene bank with the multi-cell pathogenic gene set hybrid cell line as the target pathogenic gene collection unit is established.
[0009] The beneficial effects of the present invention are: creating a cell line hybridoma technology, realizing the fusion of multiple cell lines and joint drug screening, and being used to construct a hybrid cell line with a multi-cell pathogenic gene collection, so that the target pathogenic genes of multiple cell lines are collected in the hybrid cell line, and then constructing a new gene library with the hybrid cell line as the target pathogenic gene collection unit; because the hybrid cell line inherits the SV40LT immortalization gene and the hTERT immortalization gene of the fused cell line at the same time, it has better immortalization performance, longer life, and is more suitable for amplifying the target gene through unlimited passage and preparing quality control materials for large-scale use; because the designed technical solution is to construct cell lines containing the G418 screening marker respectively and a cell line containing PM screening markers and fusing cell lines containing different screening markers into a hybrid cell line containing both screening markers, so that the hybrid cell line can resist the combined screening of G418 and PM, that is, a new technology for combined screening of G418 and PM drugs is established, which is used to screen out the target hybrid cell line from the cell line fusion product, so that the construction of the multi-cell pathogenic gene set hybrid cell line of the present invention is realized; because each multi-cell pathogenic gene set hybrid cell line contains target pathogenic genes of multiple diseases, it is possible to replace several, dozens, hundreds or even more existing cell lines with one hybrid cell line, so as to more effectively collect, manage and use the hybrid cell lines.
[0010] For example, according to the quality control requirements of the same batch detection of multiple genetic diseases, the quality control genes must correspond to the genes being tested, which requires the use of multiple quality control cell lines to meet the types of quality control genes. Assuming that 10 cell lines are required using the prior art, if the present invention fuses these 10 cell lines into one pathogenic gene collection hybrid cell line, then only one hybrid cell line needs to be collected, cultured, and equipped to meet the types and requirements of quality control genes, which not only greatly improves work efficiency, but also the prior art is difficult to implement in actual work because it requires the use of many cell lines at the same time. The present invention can be used to solve this technical problem.
[0011] In addition, the present invention discovered a weak positive DNA band similar to the human E49 gene derived from mouse tumor sp2 / 0 cells. The weak positive DNA band indicates that mouse tumor sp2 / 0 cells can be used to prepare quality control genes for human DMD gene detection. A new approach for preparing human-derived gene detection quality control materials using animal-derived cells has been discovered, solving the problem of the source of quality control materials for rare disease gene detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 It is a structural diagram of the vectors pLXSN-SV40LT and pLPCX-hTERT used in the present invention.
[0013] Figure 2 This is the growth characteristic of the G418-resistant amniotic fluid cell line constructed by the present invention.
[0014] Figure 3 It is a technical circuit for the fusion of human B cell line and sp2 / 0 cell of the present invention.
[0015] Figure 4 It is a hybridoma cell line clone formed by fusion of the human B cell line of the present invention and sp2 / 0 cell.
[0016] Figure 5 It is the DNA electrophoresis diagram of the target gene of the hybridoma cell line of the present invention.
[0017] Figure 6 It is the amniotic fluid cell line and the amniotic fluid cell line fusion technology circuit of the present invention.
[0018] Figure 7 It is a hybrid amniotic fluid cell line clone of the present invention.
[0019] Figure 8 This is the growth state of the parental amniotic fluid cell line of the present invention when it is passaged to the 3rd day of the 50th generation.
[0020] Fig. 9 It is the growth state of the hybrid cell line of the present invention at the 3rd day after the 50th generation.
[0021] Figure 1 It means that SV40LT is inserted into the EcoRI / BamHI site of the vector pLXSN. The vector carries the Neo resistance gene, which can inactivate the aminoglycoside antibiotic G418, making the transfected cell line resistant to G418 selection; hTERT is inserted into the EcoR I / NotI site of pLPCX. The vector carries the puro resistance gene, which can inactivate puromycin, making the transfected cell line resistant to puromycin selection.
[0022] Figure 2 It indicates that the G418-resistant amniotic fluid cell line constructed by SV40LT transfection of the present invention is in a spindle-shaped, adherent, and infinite growth state, and the growth characteristics of the amniotic fluid cell lines constructed by SV40LT and hTERT transfection are consistent.
[0023] Figure 3 It represents the steps of fusing human B cell lines transfected with Epstein-Barr virus with G418-resistant sp2 / 0 cells, and screening the cell fusion products by combining G418 and HAT, wherein G418 only kills unfused B cell lines and their own fused cells, and HAT only kills sp2 / 0 cells and their own fused cells, and only hybrid cell lines that have HAT and G418 resistance due to inheriting the entire genome of the B cell line and sp2 / 0 cells, including the HAT resistance gene and the G418 resistance gene, can survive.
[0024] Figure 4This means that after the B cell line of the present invention is fused with the sp2 / 0 cells, the unfused B cell line and its own fused cells in the fusion product are killed by G418, the unfused sp2 / 0 cells and its own fused cells are killed by HAT, and only hybrid cells that inherit the HAT resistance of the B cell line and the G418 resistance of sp2 / 0 can survive, thereby obtaining cell clones.
[0025] Figure 5 The DNA electrophoresis diagram of the present invention is divided into the following from left to right: the first column is set as Mark; the second column is the positive control group, in which 47, E49, and E50 genes are all positive bands; the third column is the DMD group, in which the human lymphocyte E47 gene is positive, while the E49 and E50 genes are both negative; the fourth group is the sp2 / 0 group, in which the mouse sp2 / 0 cells show weak positivity for the E49 gene; the fifth group is the DMD and sp2 / 0 hybrid strain group, indicating that the hybridoma cell line formed by the fusion of human lymphocytes and mouse sp2 / 0 cells inherits all the genes of human lymphocytes and mouse sp2 / 0 cells, including the E47 gene from human lymphocytes and the E49 gene from mouse sp2 / 0 cells, so it shows E47 gene positivity and E49 gene weak positivity. It should be pointed out that when the hybridoma cell line is used to make a quality control material for genetic testing, the E49 weak positive band from mouse sp2 / 0 cells cannot be considered as an interfering band, because the band itself can be used as a positive quality control control for human pathogenic gene testing. For example, when the hybrid cell line is tested simultaneously with patient samples, if the band is tested stably and weakly positive each time, it means that the test results of the same batch are accurate and reliable. If the band does not appear in a certain test result, the cause of the error should be found out.
[0026] Figure 6 The invention discloses an experimental circuit for fusing amniotic fluid cell lines, including constructing vectors, transfecting amniotic fluid cells and screening amniotic fluid cell lines A and B. The fusion products of amniotic fluid cell lines A and B are A, AA, B, BB and AB. After joint screening by PM and G418, a hybrid cell line AB is obtained. When AB is fused with the amniotic fluid cell line again, a multicellular hybrid cell line is obtained.
[0027] Figure 7It represents a hybrid cell line clone formed by the fusion of amniotic fluid cell lines A and B of the present invention, wherein the amniotic fluid cell line A can resist PM but cannot resist G418 due to transfection of the pLPCX-hTERT vector, and the amniotic fluid cell line B can resist G418 but cannot resist PM due to transfection of the pLXSN-SV40LT vector. Therefore, when G418 and PM are used for joint screening, the fusion products A and AA of the two amniotic fluid cell lines A and B are killed by G418, while B and BB are killed by PM. Only the hybrid cell line AB that inherits the whole genome of the amniotic fluid cell lines A and B and thus has both G418 and PM resistance can survive. The formed hybrid cell line is spindle-shaped, adherent, and grows indefinitely, and the cell size and morphology are basically consistent with the parental cell line.
[0028] Figure 8 This indicates that the parental amniotic fluid cell line constructed by transfection with pLXSN-SV40LT in the present invention had a confluence of 50% at the 3rd day of the 50th generation.
[0029] Fig. 9 This indicates that the adherent growth confluence of the hybrid cell line of the present invention reached 85% on the third day after the 50th generation. DETAILED DESCRIPTION
[0030] Combine the following Figures 1 to 9 The present invention is described in detail, and the present invention includes but is not limited to the following technical solutions and methods.
[0031] 1. Construction of vector 1.1. Construction of vectors expressing G418 resistance gene and SV40LT gene SV40 DNA (strain 766) was used as a template, the upstream primer was 5'-GCCCAGGATCCTTAACAACAACAACAAT-3', and the downstream primer was 5'-ACGCTGAATTCCCTCTGAGCTAT-3'. The SV40 LT high-fidelity long fragment was amplified by PCR. The SV40 LT PCR product and the pLXSN retroviral vector were double-digested with EcoR I / BamH I, ligated, transformed, screened and sequenced to obtain the recombinant vector pLXSN-SV40LT ( Figure 1 ).
[0032] 1.2. Construction of vectors expressing PM resistance gene and hTERT gene The PIRES2-EGFP-hTERT plasmid was digested with EcoR I to obtain the hTERT cDNA fragment, which was then dephosphorylated and subcloned into the EcoR I site of the pLPCX vector ( Figure 1), connected with T4 DNA ligase at 22°C, transformed into competent E. coli DH5-alpha Escherichia coli, cultured at 37°C overnight, selected colorless colonies for inoculation, and expanded and cultured after restriction digestion and sequencing identification. The hTERT-containing Escherichia coli was purified with Endotoxin-Free plasmid to obtain the recombinant vector pLPCX-hTERT that can express PM resistance gene and hTERT immortalization gene.
[0033] 1.3. Construction of other gene expression vectors.
[0034] Similarly, gene expression vectors such as pBABE-hTERT and pBABE-SV40LT are constructed, which carry cell immortalization genes such as hTERT or SV40LT genes and antibiotic resistance genes such as penicillin Ampr resistance gene, kanamycin Kanr resistance gene, tetracycline Tetr resistance gene, streptomycin Strr resistance gene, chloramphenicol Cmlr resistance gene, etc.
[0035] 2. Construction of cell lines 2.1. Construction and screening of recombinant retroviral PT67 cell lines and determination of viral titers Take 10ug of each of the pLPCX / hTERT and SV40LT / pLXSN recombinant vectors, transfect PT67 cells with the standard calcium phosphate precipitation method for 24h, treat with 10% DMSO for 2min, replace with fresh culture medium, and pick cell clones 72h after transfection, expand the culture, collect the culture supernatant, and store it at -70℃. -2 , 10 -4 , 10 -6 After infection and drug screening, the virus titers of the two cell supernatants were 2.0×10 7 and 8×10 5 .
[0036] 2.2. Construction of G418-resistant amniotic fluid cell line The amniotic fluid cells of the case containing the target pathogenic gene were matched to about 8×10 5 The cells were inoculated at a concentration of 100 cells / mL and cultured at 5% carbon dioxide and 37°C. After 24 hours, they were infected with a recombinant retrovirus containing the SV40LT gene (Polybrene concentration was 8 ug / mL). One week later, they were screened with 200-400 ug / mL of G418 to obtain cell lines and expand the culture (Figure 2), and the cells were harvested.
[0037] 2.3. Construction of PM-resistant amniotic fluid cell line The amniotic fluid cells of the case containing the target pathogenic gene were matched to about 8×10 5The cells were inoculated at a concentration of 100 cells / mL and cultured at 37°C with 5% carbon dioxide. After 24 hours, they were infected with a recombinant retrovirus containing the hTERT gene (Polybrene concentration was 8 ug / mL). After one week, they were screened with 1.5 ug / mL to 2.5 ug / mL of puromycin. After clones appeared, they were expanded and cultured (same as Figure 2) and the cells were harvested.
[0038] 2.4. Construction of EB virus-transfected B lymphocyte cell line Referring to relevant literature, B lymphocyte cell lines carrying different pathogenic genes were constructed by Epstein-Barr virus transfection.
[0039] 2.5. Identification of amniotic fluid cell lines The morphology of the cell lines was observed under phase contrast microscope, transmission electron microscope and scanning electron microscope. The hTERT and SV40LT genes were detected by Western blotting to observe whether white bands appeared at the relative molecular mass of 120,000 and 93,000, respectively. The cell lines were observed to observe whether they showed typical "S"-shaped or "dome"-shaped growth characteristics. The chromosome karyotypes of the 6th, 10th, 20th and 44th generation amniotic fluid cell lines were observed to be diploid or similar to the primary cells. The amniotic fluid cell lines were observed to form clones in soft agar (the cell lines could not grow in soft agar). The 6th, 10th, 20th and 44th generation amniotic fluid cell lines were inoculated into 4 nude mice, with 1×10 6 The cell number was increased. No tumor formation was observed after 6 months, while ascites and tumors appeared in the control group after 3 to 4 months. The tumorigenicity test of the cell line was carried out. The target pathogenic gene of the hybridoma was detected by NGS, Sanger, qPCR or DNA electrophoresis to observe whether the target gene of the primary cell was retained.
[0040] 2.6. Construction of mouse sp2 / 0 cell line Referring to relevant literature, sp2 / 0 cells were prepared into about 8×10 5 The cells were inoculated at a concentration of 100 cells / mL and cultured at 5% carbon dioxide and 37°C. After 24 hours, the cells were infected with a recombinant retrovirus (vector) containing the SV40LT gene (Polybrene concentration was 8 ug / mL). After one week, the cells were screened with 200-400 ug / mL of G418 to obtain the cell line and expand the culture to harvest the sp2 / 0 cell line.
[0041] 2.7. Construction of other animal cell lines Similarly, vectors or Epstein-Barr virus transfection are used to construct animal cell lines with human pathogenic gene sequences and animal cell lines with sequences homologous to normal human genomes, including mouse, chimpanzee, gorilla, orangutan, and gibbon animal cell lines.
[0042] 3. Construction of hybrid cell lines expressing pathogenic genes 3.1. Fusion of human B cell line with mouse sp2 / 0 cells to construct pathogenic gene collection hybridoma cell line ( Figure 3 ) 3.1.1. The human B cell lines constructed by Epstein-Barr virus transfection, including GJB2:c.109G>A(hom), DMD(E47), DMD(E49), GJB2:c.235delC(hom), HBB:c.52A>T(het), PAH:c.728G>A(het), F8:c.6046C>T(het), etc., were numbered B 1 , B 2 , B 3 , B 4 , B 5 , B 6 ..., to form 8×10 5 The cell concentration.
[0043] 3.1.2. Cultivate the cell line to be fused, for example, culture B 1 and G418-resistant sp2 / 0 cells.
[0044] 3.1.3. Sp2 / 0 (abbreviated as S) and B 1 Mix in equal amounts, the cell fusion products induced by the fusion agent include SB 1 , S, SS, B 1 , B 1 B 1 , combined screening with HAT and G418, the former kills S and SS, the latter kills B 1 and B 1 B 1 , only hybridoma SB 1 Because it inherits the entire genome of the parental cell, it has both the G418 resistance of sp2 / 0 and the B 1 The HAT resistance can survive, and the hybridoma cell line clones screened are as follows Figure 4 The results of genetic testing of hybridoma cell lines are shown in Figure 5 Among them, the E49 gene derived from sp2 / 0 cells is weakly positive. This band can be used as a quality control control for DMD gene detection. When the cell line is tested simultaneously with patient samples, if the test results of this band are stable and weakly positive each time, it means that the test results of the same batch are accurate.
[0045] 3.1.4. Take B 2 and the SB constructed above 1 When the concentration of fused cells is reduced to 1 / 3 to 1 / 2, the same operation is performed as above. At this time, only G418 is used for screening to kill B 2 , B 2 B 2 , obtained hybridoma cell line SB 1 , SB1 B 2 , SB 1 SB 1 .
[0046] 3.1.5. Select clones grown from single or very few cells, and perform monoclonal cell screening and target pathogenic gene screening by multiple dilution method, from which clones containing target pathogenic gene B are screened. 1 and B 2 Hybridoma cell line SB 1 B 2 .
[0047] 3.1.6. Obtain SB 1 B 2 and B 3 After the concentration of fused cells is reduced to 1 / 3 to 1 / 2, the above operation is repeated, and clones grown from single cells are selected by G418 screening, from which clones containing the target gene B are screened. 1 , B 2 and B 3 Hybridoma SB 1 B 2 B 3 .
[0048] 3.1.7. Repeat the above steps to sequentially construct hybridoma cell lines that contain multiple B cell line target genes.
[0049] 3.2. Fusion of human B cell line with human amniotic fluid cell line to construct pathogenic gene set hybrid cell line 3.2.1. Human B cell lines constructed by EB virus transfection are numbered as above, coded as B 1 , B 2 , B 3 , B 4 , B 5 , B 6 ..., G418-resistant human amniotic fluid cell lines including HBA, HBB, SLC26A4, MT-RNR1, GBA, SMN1, SMN2, T13, T18, T21, 45,X, 46,XX, t(13;18)(q12;q21) were constructed by transfection with SV40LTag-pcDNA3.1(-) vector and numbered Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 …, respectively, to form 8×10 5 The cell concentration.
[0050] 3.2.2. Take Y 1 and B 1, using electrofusion to induce cell fusion, the codes of the simulated products include Y 1 B 1 , Y 1 , Y 1 Y 1 , B 1 , B 1 B 1 , screened with G418, killing B 1 , B 1 B 1 .
[0051] 3.2.3. Select clones grown from single or very few cells from the 96-well plate, perform monoclonal cell screening and target pathogenic gene verification by multiple dilution method, and select clones from Y 1 B 1 , Y 1 , Y 1 Y 1 Screening out the target hybrid cell line Y 1 B 1 .
[0052] 3.2.4. Take Y 1 B 1 and B 2 The hybrid cell line Y, which combines the target pathogenic genes of the three cell lines, was obtained by electrofusion, G418 screening, monoclonal cell screening and monoclonal target gene detection. 1 B 1 B 2 .
[0053] 3.2.5. Repeat the above steps to obtain the target gene set hybrid cell line Y 1 B 1 B 2 B 3 , Y 1 B 1 B 2 B 3 B 4 ….
[0054] 3.3. Press Figure 6 Operation, fusion of amniotic fluid cell lines, construction of pathogenic gene collection hybrid cell lines 3.3.1. G418-resistant human amniotic fluid cell line constructed by transfection with SV40LTag-pcDNA3.1(-) vector is numbered as above, coded as Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 ..., PM-resistant human amniotic fluid cell line constructed by transfection with pLPCX-hTERT vector is numbered y1 ,y 2 ,y 3 ,y 4 ,y 5 …, respectively, to form 8×10 5 The cell concentration.
[0055] 3.3.2. Set the target gene to y 1 and the target gene is Y 1 The amniotic fluid cell line was electrofused, and the products included Y 1 y 1 , Y 1 , Y 1 Y 1 ,y 1 ,y 1 y 1 , PM and G418 were combined for screening, PM killed Y 1 , Y 1 Y 1 , G418 kills y 1 ,y 1 y 1 , only Y 1 y 1 Because they inherit the G418 and PM resistance genes from the two parental cell lines, they can survive. The hybrid cell line clones screened are as follows Figure 7 .
[0056] 3.3.3. Cells to be fused Y 2 and Y 1 y 1 The cell concentration is reduced to 1 / 3 to 1 / 2, and the electrofusion product is y 1 Y 1 ,y 1 Y 1 y 1 Y 1 , Y 2 , Y 2 Y 2 ,y 1 Y 1 Y 2 , use PM to filter and kill Y 2 , Y 2 Y 2 , obtain hybrid cell line y 1 Y 1 ,y 1 Y 1 y 1 Y 1 ,y 1 Y 1 Y 2 .
[0057] 3.3.4. Select the clones that are transparent, non-shrinking, and grown from a single or very few cells in the 96-well plate, and perform monoclonal cell screening and pathogenic gene detection by multiple dilution method to obtain the clones with pathogenic genes as y 1 , Y 1 , Y 2 Hybrid cell line 1 Y 1 Y 2 .
[0058] 3.3.5. Repeat the above steps to construct hybrid cell lines with different pathogenic gene combinations.
[0059] 3.3.6. Fuse DMD patient (amniotic fluid) cells with strong E47 gene positive and DMD patient (amniotic fluid) cells with weak E49 gene positive to obtain a hybrid cell line containing both E47 strong positive and E49 weak positive pathogenic gene sets; 3.3.7. Six patient amniotic fluid (lymphoid) cell lines, each containing the pathogenic gene GJB2: c.109G>A(hom), PAH: C.728G>A(het), GJB2: c.235delC(hom), F8: C.6046C>T(het), HBB: c52A>T(het) or LMX1B: C.712_714delTTC, were fused into one pathogenic gene collection hybrid cell line that combines the target genes of the six cell lines.
[0060] 4. Comparison of immortalization properties of parental amniotic fluid cell lines and their hybrid cell lines (Table 1) 4.1. Randomly select the parental amniotic fluid cell line constructed by SV40LT and hTERT gene transfection in the present invention and cultured to the 50th generation, and prepare a concentration of 1×10 5 At the same time, the hybrid cell line constructed by the present invention and cultured to the 50th generation was randomly selected and prepared into a concentration of 1×10 5 3 mL of cell suspension was inoculated into 25 cm2 culture flasks and cultured under the same conditions until the third day. The adherent cell lines were photographed under an inverted microscope. Figure 8 and Fig. 9 As shown, the confluence of the parental cell line is about 50-55%, while the confluence of the hybrid cell line is about 85%. It is speculated that this is because the hybrid cell line contains both the genes SV40LT and hTERT and has a better confluence, faster cell growth, and better immortalization performance.
[0061] 4.2. The parental and hybrid cell lines grown adherently were digested with 0.5% trypsin, respectively, and after dilution at the same multiple, the cells were counted using a hemocytometer. The cell numbers of the former and the latter are shown in Table 1.
[0062] Table 1 Comparison of immortalization properties of parental (amniotic fluid) cell lines and their hybrid cell lines 5. Construction of a hybrid cell line gene library containing pathogenic genes By constructing hybrid cell lines of pathogenic gene sets, the target pathogenic gene sets of multiple parental cell lines are collected in their respective hybrid cell lines, and then the hybrid cell lines of pathogenic gene sets are collected in -196℃ liquid nitrogen to establish a rare disease or birth defect gene library with various hybrid cell lines as collection carriers or collection units of various target pathogenic genes.
[0063] 6. Application of Pathogenic Gene Collection Hybrid Cell Lines 6.1. Target gene verification of hybrid cell lines: Use standard products or reference methods Sanger / MLPA / qPCR to verify each variant site in the hybrid cell line, adjust the cells or their DNA, determine the detection rate / missed diagnosis rate / reproducibility of each mutation site in the same batch of cells, and determine the "judgment value" (cut-off value) to meet the clinical needs of the gene being screened.
[0064] 6.2. Preparation and application of pathogenic gene panel hybrid cell line quality control 6.2.1. Prepare “judgment value” quality control materials: used to verify the development and quality uniformity of the kit.
[0065] 6.2.2. Prepare weak positive quality control materials: keep the concentration close to the “judgment value” and test whether the weak positive quality control materials can be used to verify slight quality changes of instruments, reagents and detection methods.
[0066] 6.2.3. Prepare high, medium and low concentration quality control materials: Make the concentration of quality control materials within the linear range for monitoring quantitative detection; make the concentration of quality control materials 2-4 times the lower limit of the detection method for verifying qualitative detection.
[0067] 6.2.4. Human cell lines including tumor cells or animal cell lines with similar sequences to human pathogenic genes can be used as positive control materials, or animal cell lines with highly homologous sequences to normal human genes can be used as normal control materials.
[0068] 6.2.5. For verification of methodological performance: prepare 3 quality control materials close to the detection limit, test them 3 times in the same batch or different batches, and observe whether the target gene is repeatedly detected, to verify the precision; use several methods to compare the whole genome or whole exome of the quality control materials, compare the base accuracy or target gene detection rate, to verify the sensitivity: prepare 5 lower limit quality control materials, test them 12 times each, calculate the target gene detection rate, to verify the accuracy of the method.
[0069] 6.2.6. Used to monitor the reliability of testing of the same batch of patients: select judgment values, weak positives, or high, medium, and low concentration quality control materials, and test them under the same conditions as patient samples for 20 consecutive times (days) to observe whether the multi-gene mutation sites of the quality control materials are detected each time, analyze the reproducibility, false positives, and false negatives of the quality control tests, and monitor the reliability of the same batch of tests.
[0070] 6.2.7. For building an indoor quality control chart: The quality control material is used together with the patient sample to perform 20 tests on the target gene, converted into a quantitative value, and the mean, standard deviation (1SD, 2SD and 3SD) are calculated to create an indoor quality control chart. Then, starting from the 21st test, the quality control results are "pointed" at the corresponding position of the quality control chart, and the points are connected. The quality control result judgment is: ① Warning: 1 quality control exceeds the mean ±2s. ② Out of control: 1 quality control exceeds the mean ±3s, two consecutive quality controls exceed the mean +2s or -2s, 1 quality control exceeds the mean +2s and another quality control exceeds the mean -2s, four consecutive quality controls simultaneously exceed the mean +1s or the mean -1s, and 10 consecutive quality controls fall on the same side of the mean.
[0071] 6.2.8. Used for monitoring indoor quality control: Use judgment value quality control materials, weak positive quality control materials or high, medium and low concentration quality control materials and quality control charts for monitoring indoor quality control. If false positive / false negative quality control is found, the cause should be found and the error should be eliminated, including replacing reagents, calibrating instruments, checking operations, retesting, etc., so that quality control can be "under control" before retesting and issuing reports.
[0072] 6.2.9. For inter-laboratory quality survey of prenatal diagnosis: The quality control organization selects the pathogenic gene set hybrid cell line of the present invention according to the evaluation purpose, and regularly distributes it to each participating laboratory to assess whether each laboratory can accurately detect various target pathogenic genes in the hybrid cell line. Its advantage is high efficiency and saving: only one or two hybrid cell lines can cover many target pathogenic genes that need to be distributed by many cell lines, and mailing one hybrid cell line replaces the need to mail many cell lines.
Claims
1. A hybrid cell line containing multiple pathogenic genes and a gene library thereof, characterized in that: A vector carrying the SV40LT gene and its screening marker and a vector carrying the hTERT gene and its screening marker are constructed, and cells of patients or animals with different genetic diseases are transfected respectively to construct cell lines carrying different screening markers and different pathogenic genes. The different cell lines are subjected to multi-cell fusion and cell line joint screening to obtain a multi-cell pathogenic gene set hybrid cell line that combines the target genes of each parental cell line, the SV40LT gene and the hTERT gene. The hybrid cell line is used to construct a new gene library with the multi-cell pathogenic gene set hybrid cell line as the gene collection unit, so that each hybrid cell line has better immortalization performance, better collection, management, application or gene detection quality control material preparation effect due to carrying multiple disease target genes and the SV40LT gene and the hTERT gene at the same time.
2. A multi-cell pathogenic gene set hybrid cell line and gene library thereof according to claim 1, characterized in that: The vectors include a pLPCX-hTERT vector with a PM resistance gene as a screening marker and hTERT as an immortalization gene, and a pLXSN-SV40LT vector with a G418 resistance gene as a screening marker and SV40LT as an immortalization gene.
3. A multi-cell pathogenic gene set hybrid cell line and gene library thereof according to claim 1, characterized in that: The selection marker refers to the antibiotic resistance gene carried by the gene expression vector, including penicillin Ampr resistance gene, kanamycin Kanr resistance gene, tetracycline Tetr resistance gene, streptomycin Strr resistance gene or chloramphenicol Cmlr resistance gene.
4. A multi-cell pathogenic gene set hybrid cell line and gene library thereof according to claim 1, characterized in that: The combined screening refers to multi-cell fusion of a cell line with a PM resistance gene as a screening marker and a cell line with a G418 resistance gene as a screening marker, and the use of PM and G418 combined screening to obtain a multi-cell pathogenic gene set hybrid cell line that inherits the entire genome of each parental cell line, including PM and G418 resistance genes, and is resistant to PM and G418 combined screening.
5. A multi-cell pathogenic gene set hybrid cell line and gene library thereof according to any one of claims 1 and 4, characterized in that: The hybrid cell line is obtained through monoclonal cell screening and target gene detection screening.
6. A hybrid cell line of multiple cell pathogenic gene sets and its gene library according to claim 1, characterized in that: The animal cells refer to animal-derived cells from mice, chimpanzees, gorillas, orangutans, and gibbons that can be used to prepare positive control quality control materials for pathogenic gene detection, or animal-derived cells that can be used to prepare normal control quality control materials for pathogenic gene detection.
7. A multi-cell pathogenic gene set hybrid cell line and gene library thereof according to any one of claims 1, 5 and 6, characterized in that: The hybrid cell line is prepared by fusion of human-derived cells, by fusion of animal-derived cells, or by fusion of human-derived cells and animal-derived cells; the hybrid cell line contains a human target gene that can be used to prepare a genetic detection quality control material, an animal-derived gene that is similar to the human target gene, or an animal-derived gene that is homologous to a normal human gene sequence.
8. A multi-cell pathogenic gene set hybrid cell line and gene library thereof according to any one of claims 1 and 7, characterized in that: The hybrid cell lines include human-mouse cell fusion hybrid cell lines formed by the fusion of human cells and mouse tumor cells.
9. A multi-cell pathogenic gene set hybrid cell line and gene library thereof according to any one of claims 1 and 8, characterized in that: The hybrid cell line is used to amplify human target genes or to prepare human DMD gene detection quality control substances derived from mouse tumor cells; the human DMD gene detection quality control substances refer to mouse genes that can be used as positive controls for E49 gene detection.
10. A multi-cell pathogenic gene set hybrid cell line and gene library thereof according to any one of claims 1 to 9, characterized in that: The hybrid cell line is obtained by the following experimental steps: (1) constructing vectors carrying different immortalization genes and their antibiotic resistance selection markers, such as constructing a vector pLPCX-hTERT that can express the puromycin PM resistance gene selection marker and the hTERT immortalization gene, and constructing a vector pLXSN-SV40LT that can express the G418 resistance gene selection marker and the SV40LT immortalization gene; (2) Transfecting human cells including tumor cells or animal cells of pigs, mice, chimpanzees, gorillas, orangutans, and gibbons with vectors of different selection markers, for example, using the vectors to transfect human amniotic fluid cells with pathogenic genes A or B, respectively, and screening with G418 at a concentration of 200 ug / mL to 400 ug / mL or PM at a concentration of 1.5 ug / mL to 2.5 ug / mL, respectively, to obtain PM-resistant amniotic fluid cell line A with target pathogenic gene A and G418-resistant amniotic fluid cell line B with target pathogenic gene B; (3) Fusion of cell lines carrying different selection markers and pathogenic genes, for example, fusion of amniotic fluid cell lines A and B, and screening of the fusion product of A and B using PM and G418. Only hybrid cell lines AB that inherit genes from both A and B and carry both G418 and PM resistance genes can survive; (4) Obtain hybrid cell lines containing different target gene sequences through monoclonal cell screening, pathogenic gene detection and sequence homology comparison, including cell lines containing human homologous gene sequences prepared from non-human cells; (5) The hybrid cell line is fused with cell lines containing different pathogenic genes for multiple times, and the hybrid cell line is screened by PM, G418 and / or HAT, as well as monoclonal cell screening and pathogenic gene detection to obtain a hybrid cell line with multiple cell pathogenic genes; (6) DMD patient lymphocytes that are strongly positive for E47 and mouse tumor cells that are weakly positive for E49 are fused to obtain a hybrid cell line that contains the pathogenic genes of E47 and E49; (7) The lymphocyte cell lines of patients with GJB2: c.109G>A(hom), PAH: C.728G>A(het), GJB2: c.235delC(hom), F8: C.6046C>T(het), HBB: c52A>T(het), and LMX1B: C.712_714delTTC were fused to obtain a multi-cell pathogenic gene hybrid cell line; (8) Establish a new gene bank with hybrid cell lines containing multiple pathogenic genes as target gene collection units, so that each hybrid cell line contains the target pathogenic genes of multiple cell lines, thus achieving efficient collection and application.
